BiomeBank announces regulatory approval for donor derived microbiome drug

Got a Question? Request a Callback

BiomeBank announces regulatory approval for donor derived microbiome drug

Whitley Workstation customer, BiomeBank, receives TGA (Therapeutic Goods Administration) approval for a donor derived microbiome drug. The drug - BIOMICTRA - will be used for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection. A recent article in the publication Microbiome Times tell the story:

https://www.microbiometimes.com/biomebank-announces-regulatory-approval-for-donor-derived-microbiome-drug/

BiomeBank, based in Adelaide, Australia, are the proud owners of a Whitley A85 HEPA Workstation, which will be joined by an A55 Workstation early in 2023.

Chat

Choose a Country

If you are based in Germany or Australia, please select the website of our subsidiary company there. A different selection of products is available in these countries. Otherwise, please select ‘English’ and you will be able to find your local distributor in the ‘Overseas Distributors’ section.

Share this

Please select your preferred language from the list below

Login

Don't have an account? Click Here

Forgot your password? Click Here